Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 12/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.46 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.46 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12812066 | 0.90 | ATM (0.46) | GAAPIK3CAEPHX2MTORGBA1 | |
| SCHEMBL10178945 | 0.88 | KDR (0.43) | GAAPIK3CAPIK3CDEPHX2MTOR | |
| SCHEMBL13276289 | 0.87 | MTOR (0.60) | PIK3CAPIK3CDMTORPIK3CGPIK3CB | |
| SCHEMBL1442429 | 0.87 | GBA1 (0.61) | PIK3CAPIK3CDMTORPIK3CGGBA1 | |
| SCHEMBL1443590 | 0.86 | MAPK14 (0.50) | PIK3CAPIK3CDMTORPIK3CGATR | |
| SCHEMBL1442827 | 0.85 | GBA1 (0.61) | PIK3CAPIK3CDMTORPIK3CGGBA1 | |
| SCHEMBL1444071 | 0.85 | PIK3CA (0.67) | PIK3CAPIK3CDMTORPIK3CG | |
| SCHEMBL1442442 | 0.85 | MTOR (0.53) | PIK3CAPIK3CDMTORPIK3CGGBA1 | |
| SCHEMBL1442936 | 0.84 | GBA1 (0.63) | PIK3CAGBA1GLA | |
| SCHEMBL12812451 | 0.83 | GBA1 (0.48) | GAAPIK3CAPIK3CDMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | claimed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | claimed |
| EP-2473498-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-11 | — | — | EP | claimed |
| WO-2011026579-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-10 | — | — | WO | claimed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| EP-2473498-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026579-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | ABL1, TYK2, JAK2 | GAA 1274/4885PIK3CA 181/4885PIK3CD 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.